Monivent (MONI) Q1 2025 earnings summary

Executive summary

• Signed a global distribution agreement with 3B Scientific for Neo Training, expanding global reach and complementing the Dräger partnership.

• Implemented a new commercial strategy, shifting from many local distributors to a few global partners.

• Successfully completed a rights issue, raising SEK 13.5 million before costs, strengthening the cash position.

• Ongoing regulatory work for MDR transition and FDA submission, with preparations for Neo100 launch in Dräger's sales channels.

Financial highlights

• Net sales for Q1 2025 were SEK 668k, up from SEK 460k in Q1 2024.

• Operating costs decreased to SEK 2,962k from SEK 3,527k year-over-year.

• EBIT improved to SEK -2,173k from SEK -3,059k in the same quarter last year.

• Cash and cash equivalents at period end were SEK 4,400k.

• Result per share was SEK -0.04, compared to SEK -0.20 in Q1 2024.

Outlook and guidance

• Focus on global expansion through strategic partnerships with Dräger and 3B Scientific.

• Anticipates broader market access for Neo Training and Neo100, pending regulatory approvals.

• Continued efforts on MDR compliance and FDA market approval.